Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by Freedom Investment Management Inc.

Freedom Investment Management Inc. grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 51.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 17,806 shares of the biopharmaceutical company's stock after acquiring an additional 6,040 shares during the period. Freedom Investment Management Inc.'s holdings in Bristol-Myers Squibb were worth $1,007,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Capital International Ltd. CA lifted its holdings in Bristol-Myers Squibb by 0.8% during the fourth quarter. Capital International Ltd. CA now owns 60,180 shares of the biopharmaceutical company's stock valued at $3,404,000 after purchasing an additional 452 shares during the last quarter. Capital Group Private Client Services Inc. lifted its stake in shares of Bristol-Myers Squibb by 73.3% during the 4th quarter. Capital Group Private Client Services Inc. now owns 816,602 shares of the biopharmaceutical company's stock valued at $46,187,000 after buying an additional 345,464 shares in the last quarter. Capital International Investors boosted its holdings in Bristol-Myers Squibb by 7.5% in the 4th quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock worth $2,593,940,000 after buying an additional 3,218,865 shares during the period. Capital International Sarl raised its holdings in Bristol-Myers Squibb by 31.7% during the 4th quarter. Capital International Sarl now owns 154,092 shares of the biopharmaceutical company's stock valued at $8,715,000 after acquiring an additional 37,067 shares during the period. Finally, First Commonwealth Financial Corp PA purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $227,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Trading Down 0.3 %

Shares of BMY traded down $0.13 during mid-day trading on Thursday, reaching $48.40. 11,409,292 shares of the company's stock traded hands, compared to its average volume of 12,459,383. The stock's 50-day moving average is $56.60 and its two-hundred day moving average is $56.54. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The stock has a market cap of $98.48 billion, a P/E ratio of -10.95, a P/E/G ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.55 by $0.25. The business had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. During the same quarter last year, the firm posted ($4.40) EPS. Research analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be paid a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 5.12%. Bristol-Myers Squibb's dividend payout ratio (DPR) is -56.11%.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 1,823 shares of the company's stock in a transaction on Friday, February 14th. The shares were bought at an average price of $54.84 per share, with a total value of $99,973.32. Following the transaction, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.09% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Piper Sandler started coverage on Bristol-Myers Squibb in a research note on Tuesday. They issued an "overweight" rating and a $65.00 target price for the company. Jefferies Financial Group lowered their price objective on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday. Truist Financial boosted their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday. Finally, Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.